Review Article
Drug-related toxicity in breast cancer patients: a new path towards tailored treatment?—a narrative review
Precision Cancer Medicine
2022;
5:
15
(30 June 2022)
Review Article
The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review
Precision Cancer Medicine
2022;
5:
14
(30 June 2022)
Review Article
A narrative review of the management of BRAF non-V600E mutated metastatic non-small cell lung cancer
Precision Cancer Medicine
2022;
5:
13
(30 June 2022)
Original Article
Prospective and single-blinded evaluation of the multi-cancer Carcimun-test
Precision Cancer Medicine
2022;
5:
12
(30 June 2022)
Editorial
From icing to slicing the cake: the new hope of precision medicine for lung cancer
Precision Cancer Medicine
2022;
5:
11
(30 June 2022)
Case Report
Efficacy of pembrolizumab in lung adenocarcinoma harboring non-V600E BRAF mutation: a case report
Precision Cancer Medicine
2022;
5:
10
(30 March 2022)
Case Report
Uncommon EGFR mutations: state-of-the-art and case reports
Precision Cancer Medicine
2022;
5:
9
(30 March 2022)
Case Report
ALK non-small cell lung cancer sequence of treatment: a case report
Precision Cancer Medicine
2022;
5:
8
(30 March 2022)
Case Report
Primary lung secretory carcinoma: a case report
Precision Cancer Medicine
2022;
5:
7
(30 March 2022)
Review Article
Oncogene-addicted non-small-cell lung cancer in women: a narrative review of the importance of gender-related differences in treatment outcome
Precision Cancer Medicine
2022;
5:
6
(30 March 2022)
Review Article
New driver alterations in non-small cell lung cancer: a narrative review
Precision Cancer Medicine
2022;
5:
5
(30 March 2022)
Review Article
Mechanisms of resistance after crizotinib or second-generation ALK therapy in advanced non-small cell lung cancer
Precision Cancer Medicine
2022;
5:
4
(30 March 2022)
Review Article
Role of radiation therapy in triple negative breast cancer: current state and future directions—a narrative review
Precision Cancer Medicine
2022;
5:
3
(30 March 2022)
Original Article
Outcomes of head and neck angiosarcoma with different treatment modalities: a 20-year single institutional experience
Precision Cancer Medicine
2022;
5:
2
(30 March 2022)
Editorial
ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy
Precision Cancer Medicine
2022;
5:
1
(30 March 2022)
Editorial Commentary
Squeezed into defection?—nuclear displacement by steatosis activates yes-associated protein (YAP) linked to oncogenic pathways in hepatocytes
Precision Cancer Medicine
2021;
4:
40
(30 December 2021)
Case Report
Partial hippocampal sparing whole brain radiotherapy in a patient with bilateral malignant melanoma metastases to the hippocampus: a case report
Precision Cancer Medicine
2021;
4:
39
(30 December 2021)
Review Article
A narrative review of genetic factors affecting fluoropyrimidine toxicity
Precision Cancer Medicine
2021;
4:
38
(30 December 2021)
Review Article
Empowering childhood cancer survivors through integrated, individualized health insurance education
Precision Cancer Medicine
2021;
4:
37
(30 December 2021)
Review Article
Wielding a double-edged sword in head and neck cancers—diagnosis, risk factors and mitigation strategies of radiation-induced head and neck sarcomas: a narrative review
Precision Cancer Medicine
2021;
4:
36
(30 December 2021)
Review Article
Metabolic reprogramming and cancer precision medicine: a narrative review
Precision Cancer Medicine
2021;
4:
35
(30 December 2021)
Review Article
Precision cancer medicine in China: the Fudan University Shanghai Cancer Center experience
Precision Cancer Medicine
2021;
4:
34
(30 December 2021)
Review Article
A narrative review of microRNA therapeutics: understanding the future of microRNA research
Precision Cancer Medicine
2021;
4:
33
(30 December 2021)
Review Article
FDA-led consortium studies advance quality control of targeted next generation sequencing assays for precision oncology
Precision Cancer Medicine
2021;
4:
32
(30 December 2021)
Original Article
Comparison of cancer incidence and mortality between China and the United States
Precision Cancer Medicine
2021;
4:
31
(30 December 2021)
Case Report
Massive hyper-progression during anti-PD-1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review
Precision Cancer Medicine
2021;
4:
30
(30 September 2021)
Review Article
Women treating lung cancer: a narrative review
Precision Cancer Medicine
2021;
4:
29
(30 September 2021)
Review Article
Next-generation sequencing using liquid biopsy in the care of patients with ALK-rearranged non-small cell lung cancer: a focus on lorlatinib
Precision Cancer Medicine
2021;
4:
28
(30 September 2021)
Review Article
Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches—a narrative review
Precision Cancer Medicine
2021;
4:
27
(30 September 2021)
Review Article
Sex-based heterogeneity in non-small cell lung cancer (NSCLC) and response to immune checkpoint inhibitors (ICIs): a narrative review
Precision Cancer Medicine
2021;
4:
26
(30 September 2021)
Review Article
ROS1 non-small cell lung cancer patients treatment approach
Precision Cancer Medicine
2021;
4:
25
(30 September 2021)
Review Article
A narrative review of biomarkers in advanced triple negative breast cancer
Precision Cancer Medicine
2021;
4:
24
(30 September 2021)
Review Article
Non-coding RNA regulatory networks in mesothelioma: a narrative review of their implication in innate immune signaling pathways
Precision Cancer Medicine
2021;
4:
23
(30 September 2021)
Review Article
A narrative review of predictive and prognostic biomarkers in skin tumors
Precision Cancer Medicine
2021;
4:
22
(30 September 2021)
Review Article
Malignant peritoneal mesothelioma: a narrative review of the rationale for and results of treatment using ultraradical local-regional strategy
Precision Cancer Medicine
2021;
4:
21
(30 September 2021)
Editorial Commentary
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance significantly impacts clinical outcomes
Precision Cancer Medicine
2021;
4:
20
(30 June 2021)
Editorial Commentary
PARP inhibitors beyond BRCA-mutated cancers: precision medicine at the crossroads
Precision Cancer Medicine
2021;
4:
19
(30 June 2021)
Editorial Commentary
Lung cancer screening: think pink!
Precision Cancer Medicine
2021;
4:
18
(30 June 2021)
Case Report
Effectiveness of pemetrexed-based chemotherapy and radiation therapy in RET-rearranged lung adenocarcinoma: a mono-institutional case series
Precision Cancer Medicine
2021;
4:
17
(30 June 2021)
Review Article
ROS-1 NSCLC therapy resistance mechanism
Precision Cancer Medicine
2021;
4:
16
(30 June 2021)
Review Article
Monitoring therapeutic response and resistance with liquid biopsy
Precision Cancer Medicine
2021;
4:
15
(30 June 2021)
Review Article
Non-small cell lung cancer molecular characterization of advanced disease with focus on sex differences: a narrative review
Precision Cancer Medicine
2021;
4:
14
(30 June 2021)
Review Article
A narrative review of chemotherapy in advanced triple negative breast cancer
Precision Cancer Medicine
2021;
4:
13
(30 June 2021)
Review Article
Triple negative breast cancer: emerging light on the horizon—a narrative review
Precision Cancer Medicine
2021;
4:
12
(30 June 2021)
Original Article
The use of stereotactic body radiotherapy in pulmonary carcinoid tumors: a case series
Precision Cancer Medicine
2021;
4:
11
(30 June 2021)
Editorial Commentary
BRAFV600E mutant, PD-L1 TPS 90% NSCLC: 1st line treatment with targeted therapy
Precision Cancer Medicine
2021;
4:
10
(30 March 2021)
Editorial Commentary
The role of anti-PD-1/PD-L1 monotherapy as first-line treatment of metastatic NSCLC without targetable mutations and PD-L1 TPS 1–49%
Precision Cancer Medicine
2021;
4:
9
(30 March 2021)
Editorial Commentary
Management of acquired resistance to ALK inhibitors: repeat biopsy to characterize mechanisms of resistance does not significantly impact clinical outcomes
Precision Cancer Medicine
2021;
4:
8
(30 March 2021)
Editorial Commentary
Concerns and controversies regarding ipilimumab-based immunotherapy in the first-line treatment of non-small cell lung cancer
Precision Cancer Medicine
2021;
4:
7
(30 March 2021)
Editorial Commentary
ADAURA: the role of adjuvant EGFR TKI and future consideration (Pro)
Precision Cancer Medicine
2021;
4:
6
(30 March 2021)